3 completed, 1 recruiting, 1 unknown. 1 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Non-Arteritic Anterior Ischemic Optic Neuropathy: new trials by email Literature Review of Non-Arteritic Anterior Ischemic Optic Neuropathy trials Research Report on Non-Arteritic Anterior Ischemic Optic Neuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Cenegermin, Vehicle - Non-Arteritic Anterior Ischemic Optic Neuropathy | Phase 3 | Recruiting | Dompé Farmaceutici S.p.A | 272 | 2026-07-01 | 2026-09-10 |
| Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Group A Citicoline 1000 mg oral tablet, Group B placebo oral tablet - Non-arteritic Anterior Ischemic Optic Neuropathy | Phase 4 | Completed | Valen Chia | 38 | 2017-01-16 | 2017-09-07 |
| Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients QPI-1007 at various doses - Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy | Phase 1 | Completed | Quark Pharmaceuticals | 48 | 2010-02-01 | 2013-05-13 |
| Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy Intra-vitreal injection of bevacizumab (1.25mg/0.05ml) - Non-arteritic Anterior Ischemic Optic Neuropathy | Phase 2 | Unknown | Mount Sinai Hospital, Canada | 10 | 2009-02-01 | 2012-02-08 |
| Vision Restoration Therapy (VRT) to Treat Non-Arteritic Anterior Ischemic Optic Neuropathy Vision Restoration Therapy (NOVAVISION) - Non-Arteritic Anterior Ischemic Optic Neuropathy | Not applicable | Completed | Emory University | 20 | 2005-08-01 | 2013-10-23 |
Optic Neuropathy, Ischemic (3) · Optic Atrophy (1) · Optic Atrophy, Hereditary, Leber (1) · Optic Nerve Diseases (1) · Optic Neuritis (1) · Retinal Degeneration (1)
Cardiovascular Diseases (3) · Cranial Nerve Diseases (3) · Eye Diseases (3) · Nervous System Diseases (3) · Vascular Diseases (3) · Optic Nerve Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1) · Metabolic Diseases (1) · Mitochondrial Diseases (1) · Neurodegenerative Diseases (1) · Nutritional and Metabolic Diseases (1) · Optic Atrophies, Hereditary (1)
RNA, Small Interfering (1) · Tablets (1) · cenegermin (1)
Dompé Farmaceutici S.p.A (1) · Emory University (1) · Mount Sinai Hospital, Canada (1) · Quark Pharmaceuticals (1) · Valen Chia (1)
United States (3) · Australia (1) · Canada (1) · Indonesia (1) · Israel (1) · United Kingdom (1)
Edward Margolin (1) · Rabia Ozden, MD (1) · Valen Chia, MD (1) · Valerie Biousse, MD (1)
PMID 11782957, PMID 12097797, PMID 12438935, PMID 12640353, PMID 16249960, PMID 16876158, PMID 17508035, PMID 17698200, PMID 18085470, PMID 18207164, PMID 18325025, PMID 18929133, PMID 1940961, PMID 20682167, PMID 21432836, PMID 24504829, PMID 6168928, PMID 7869846